Antithymocyte Globulin (ATG)
Atgam
Near Add Your Location
Accepting patients
Cord Blood Transplantation in Children
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Horse Anti-Thymocyte Globulin (hATG)
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
- White Blood Cell Stimulant
- Steroid
- Phase 2
Accepting patients
RAFA
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
- Allogeneic Stem Cell Transplant
- Phase 2
Not yet accepting
2 Step ATG
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Allogeneic Stem Cell Transplant
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Personalized Natural Killer Cell Therapy
Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
- Natural Killer Cells (Allogeneic)
- Phase 2
Accepting patients
Cytokine-Treated Veto Cells Post-Transplant
Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- Phase 1/2
Accepting patients
ATG Dosing for GVHD Prevention
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Reduced Intensity Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Targeted ATG Dosing Pilot Study
Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641
- Allogeneic Stem Cell Transplant
- Phase 0
Showing 1-9 of 9